The application of botulinum toxin in the treatment of overactive bladder
Keywordsurinary incontinence, botulinum toxin, overactive bladder
Urinary incontinence is an involuntary, decision-dependent urination that leads to partial or complete emptying of the bladder. The causes include overactive bladder syndrome, which is diagnosed on the basis of clinical symptoms, such as urgency to urinate, increased frequency of voiding, nocturia caused by increased reactivity of the detrusor muscle. Treatment of this condition includes, but is not limited to, pharmacotherapy, behavioral therapy, and pelvic floor exercises. It is also possible to use an innovative method of local injection of botulinum toxin into the bladder. It inhibits the release of acetylcholine, which results in the inhibition of the contractile activity of the detrusor muscle.
The aim of the study:
The purpose of the systemic review was to collect and analyze material of application of botulinum toxin in the treatment of urinary incontinence caused by overactive bladder.
Material and methods:
The work is a review of the literature on the use of botulinum toxin in the treatment of overactive bladder, published in 2002-2020.
Description of the state of knowledge:
The use of the described method gives long-lasting results compared to pharmacotherapy. In addition, it eliminates the side effects caused by drugs because the administration of drugs is reduced or discontinued. The use of botulinum toxin has many more benefits than simply improving the lives of people affected by urinary incontinence. When selecting the therapy, one should also pay attention to possible side effects resulting from the use of the described drug.
Intravesical administration by means of botulinum toxin cystoscopy is a modern, safe, effective and minimally invasive method of treating urinary incontinence, possible on an outpatient basis, allowing to improve the urodynamic parameters. Side effects are very rare. The botulinum toxin serotype A used in this method is the most studied serotype used for therapeutic purposes. The conducted research shows that over 90% of women reported a clinically significant improvement in sexual function after using the method.
Coyne KS, Sexton CC, Irwin DE i in. Effects of an overactive bladder, urinary incontinence and other lower urinary tract symptoms on quality of life, productivity at work, sexuality, and emotional well-being in men and women: study results EPIC. BJU Int 2008; 101: 1388–1395
Teleman PM, Lidfelt J, Nerband C. et al. WHILA study group. Overactive bladder: Prevalence, risk factors and relation to stress incontinence in middle aged women. BJOG. 2004;111(6):600–4.
Morrison J, Steers WD, Brading AF. et al. Neurophysiology and neuropharmacology. Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. (2nd ed) 2002:86–163.
McGrouther CW, Donaldson MM, Thompson J. et al. Etiology of overactive bladder: A diet and lifestyle model for diabetes and obesity in older women. Neurourol Urodyn. 2012;31(4):487–95
Allahdin S & N. Oo (2012) An overview of treatment of overactive bladder syndrome in women, Journal of Obstetrics and Gynecology, 32: 3, 217-221
Pannek, J. Überaktive Blase – wann welche Therapie. Urologe 2017, 56:1532–1538
Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM . 2008. Refractory idiopathic urge urinary incontinence and botulinum A injection. Journal of Urology 180:217–222.
Anger JT, Weinberg A, Suttorp MJ, Litwin MS, Shekelle PG. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. Journal of Urology 2010; 183: 2258–2264.
Jankowic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of orginal versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186.
Jankovic J., Gchwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45: 1743–1751.
Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 6: 146–151
Simpson LL. 2004. Identification of the major steps in botulinum toxin action. Annual Review of Pharmacology and Toxicology 44:167–193
Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med. 2013;36(5):402-419.
Ziegelmüller, BK, Sommer, A. & Bauer, RM Toksyna botulinowa w pęcherzu nadreaktywnym. Urolog 59, 963-972 (2020)
Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47(5):653–9
Giannantoni A, Mearini E, Del Zingaro M, Porena M. Six-year follow-up of botulinum toxin A intradetrusotial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 2009;55(3):705–11
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 231
Number of citations: 0